Nomura Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nomura Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,000	Closed	-$1.46M	–	1913
2025 Q3	$1.46M	Sell	27,000 -81,200	-75%	-$4.64M	﹤0.01%	1257
2025 Q2	$5.95M	Sell	108,200 -180,200	-62%	-$10.6M	0.01%	525
2025 Q1	$20.4M	Sell	288,400 -2,600	-0.9%	-$175K	0.04%	287
2024 Q4	$19.1M	Buy	291,000 +39,500	+16%	+$2.65M	0.03%	352
2024 Q3	$17.7M	Buy	251,500 +29,700	+13%	+$2.48M	0.04%	301
2024 Q2	$18.3M	Buy	221,800 +75,800	+52%	+$6.31M	0.04%	282
2024 Q1	$12.8M	Buy	146,000 +112,000	+329%	+$10M	0.03%	373
2023 Q4	$3.28M	Sell	34,000 -169,900	-83%	-$15M	0.01%	804
2023 Q3	$18M	Buy	+203,900	New	+$18.1M	0.05%	241
2023 Q2	–	Sell	-66,700	Closed	-$6.49M	–	1380
2023 Q1	$6.49M	Buy	+66,700	New	+$6.91M	0.02%	476
2022 Q3	–	Sell	-36,000	Closed	-$3.06M	–	1700
2022 Q2	$3.06M	Buy	+36,000	New	+$2.87M	0.01%	680
2020 Q2	–	Sell	-220,000	Closed	-$18.6M	–	1116
2020 Q1	$18.6M	Buy	+220,000	New	+$19M	0.08%	141
2014 Q4	–	Sell	-30,000	Closed	-$2.12M	–	2306
2014 Q3	$2.12M	Hold	30,000	–	–	0.01%	1074
2014 Q2	$1.85M	Buy	+30,000	New	+$1.81M	﹤0.01%	1158

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nomura Holdings's BMRN Position: Q1 2026 in Review

Nomura Holdings reduced its BioMarin Pharmaceuticals (BMRN) stake by 11% in Q1 2026, selling an estimated $225K and leaving 30,000 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #978.

Nomura Holdings first reported a position in BMRN in Q2 2013 and has held it in 42 quarters since. The position peaked at $251M in Q3 2023. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Nomura Holdings held 30,000 shares of BioMarin Pharmaceuticals worth $1.69M as of Q1 2026.
Nomura Holdings sold 3,862 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $225K.
BioMarin Pharmaceuticals made up ﹤0.01% of Nomura Holdings's portfolio in Q1 2026, its #978 holding.
Nomura Holdings first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
Nomura Holdings's BioMarin Pharmaceuticals position peaked at $251M in Q3 2023.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.